Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Jm, Cisneros Herreros"'
Autor:
M. Poyato-Borrego, M. León-López, J. Martín-González, JM. Cisneros-Herreros, D. Cabanillas-Balsera, JJ. Segura-Egea
Publikováno v:
Medicina Oral Patología Oral y Cirugia Bucal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68b84d73a7c179da0597409d841443a1
https://doi.org/10.4317/medoral.25773
https://doi.org/10.4317/medoral.25773
Autor:
María Antonia Pérez-Moreno, JA Lepe-Jiménez, JM Cisneros-Herreros, A Garcia-Avello, MV Gil-Navarro
Publikováno v:
Drug information and pharmacotherapy.
Background Antimicrobial resistance is a growing problem worldwide. Excessive and inappropriate use of antibiotics constitutes an important risk factor in the development of bacterial resistance, so discriminating use of antimicrobial agents remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f880b26fd63d99f8915fb9e6404f37d
https://doi.org/10.1136/ejhpharm-2017-000640.297
https://doi.org/10.1136/ejhpharm-2017-000640.297
Autor:
María Antonia Pérez-Moreno, R Alma-Marin, JA Lepe-Jiménez, JM Cisneros-Herreros, MV Gil-Navarro, A Garcia-Avello
Publikováno v:
Drug information and pharmacotherapy.
Background Extended spectrum beta-lactamases (ESBL) are enzymes produced by gram negative bacilli pathogens (mainly Escherichia coli and Klebsiella pneumoniae ) than confer resistance against penicillins, cephalosporins and aztreonam. Persistent expo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::195b4d833b97934b78bc173dc70ca8dc
https://doi.org/10.1136/ejhpharm-2017-000640.319
https://doi.org/10.1136/ejhpharm-2017-000640.319
Autor:
Jm, Cisneros Herreros, Cañas García-Otero E, Francisco Javier Caballero-Granado, Becerril Carral B
Publikováno v:
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::49c027a011daaed0ba830a499c18fe22
https://pubmed.ncbi.nlm.nih.gov/9844475
https://pubmed.ncbi.nlm.nih.gov/9844475
Autor:
Ildefonso Espigado, Pilar Pérez-Romero, Fáti ma de la Cruz Vicente, R. Parody Ruiz-Berdejo, A. Urbano-Ispizua, Jm. Cisneros-Herreros, Manuela Aguilar-Guisado
Publikováno v:
Blood. 112:4380-4380
INTRODUCTION: More than 50 % of alo-HSCT recipients develop CMV infection. The best technique for early detection of viral replication has not already been defined. Antigenaemia is the most used technique but it presents limitations. Quantitative RT-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6d4f8560b19a25359b251daf864abbd
https://doi.org/10.1182/blood.v112.11.4380.4380
https://doi.org/10.1182/blood.v112.11.4380.4380
Autor:
Máximo Bernabeu-Wittel, Cañas García-Otero E, Herrero Romero M, Ordóñez Fernández A, Martínez Martínez A, Pérez Bernal J, Jm, Cisneros Herreros
Publikováno v:
Europe PubMed Central
To study the infectious complications, mortality, and associated factors in heart transplant recipients.Prospective study of the first 69 heart transplantations performed from January 1991 until December 1996 in a university hospital. Description of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9a32e9810731d079e5dd9d82e826f64a
http://europepmc.org/abstract/med/10522428
http://europepmc.org/abstract/med/10522428
Autor:
Robinson P; Infectious Disease, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA., Toussi SS; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Pearl River, New York, USA., Aggarwal S; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Bergman A; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA., Zhu T; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA., Hackman F; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Sathish JG; Drug Safety Unit, Pfizer Inc, Pearl River, New York, USA., Updyke L; Drug Safety Unit, Pfizer Inc, Cambridge, Massachusetts, USA., Loudon P; Tenpoint Therapeutics, Cambridge, UK., Krishna G; El Camino Health, Mountain View, California, USA., Clevenbergh P; University Hospital Brugmann, Brussels, Belgium., Hernandez-Mora MG; Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain., Cisneros Herreros JM; Hospital Universitario Virgen Del Rocio, Sevilla, Spain., Albertson TE; UC Davis Medical Center, Sacramento, California, USA., Dougan M; Massachusetts General Hospital, Boston, Massachusetts, USA., Thacker A; Regional One Health, Memphis, Tennessee, USA., Baniecki ML; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Soares H; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Whitlock M; Early Clinical Development, Pfizer Inc, Cambridge, UK., Nucci G; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Menon S; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Anderson AS; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Binks M; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK.
Publikováno v:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Jul 10; Vol. 10 (8), pp. ofad355. Date of Electronic Publication: 2023 Jul 10 (Print Publication: 2023).
Autor:
Poyato-Borrego M; School of Dentistry, University of Sevilla C/ Avicena s/n, 41009-Sevilla, Spain segurajj@us.es., León-López M, Martín-González J, Cisneros-Herreros JM, Cabanillas-Balsera D, Segura-Egea JJ
Publikováno v:
Medicina oral, patologia oral y cirugia bucal [Med Oral Patol Oral Cir Bucal] 2023 Jul 01; Vol. 28 (4), pp. e355-e361. Date of Electronic Publication: 2023 Jul 01.
Autor:
Gil-Navarro MV; Unidad Clínica de Farmacia, Instituto de Biomedicina de Sevilla (IBIS)/Hospital Universitario Virgen del Rocío, Sevilla. Spain.. mariav.gil.sspa@juntadeandalucia.es., Gutiérrez-Urbón JM; Servicio de Farmacia, Complejo Hospitalario Universitario La Coruña, La Coruña. Spain.. mariav.gil.sspa@juntadeandalucia.es., El Fahimi N; Servicio de Farmacia, United Lincolnshire Hospitals NHS Trust, United Kingdom.. mariav.gil.sspa@juntadeandalucia.es., Cisneros-Herreros JM; Unidad Clínica de Enfermedades infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBIS)/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla. Spain.. mariav.gil.sspa@juntadeandalucia.es.
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2021 Feb 22; Vol. 45 (2), pp. 82-88. Date of Electronic Publication: 2021 Feb 22.
Autor:
Gudiol C; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. carlotagudiol@gmail.com.; University of Barcelona, Barcelona, Spain. carlotagudiol@gmail.com.; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain. carlotagudiol@gmail.com., Nicolae S; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain., Royo-Cebrecos C; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain., Aguilar-Guisado M; Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain., Montero I; Department of Haematology, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain., Martín-Gandul C; Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain., Perayre M; Pharmacy Department, Clinical Trial Unit, Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Berbel D; Microbiology Department, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Encuentra M; Biostatistics. Clinical Research Unit, Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Arnan M; Haematology Department, Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Cisneros-Herreros JM; Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain., Carratalà J; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain.
Publikováno v:
Trials [Trials] 2018 May 02; Vol. 19 (1), pp. 264. Date of Electronic Publication: 2018 May 02.